Baroreflex Activation Therapy for Heart Failure
Completed · Not applicable · NCT02627196
Conditions: Heart Failure
At a glance
- Research payments reported, 2025
- $33,665
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 1,090
About the trial
- Sponsor
- CVRx, Inc.
- Tested
- BAROSTIM NEO® System (device), Medical Management (drug)
- Dates
- Started 2016-04-19; completion 2023-10
- Results posted
- Yes
The purpose of this clinical trial (NCT02627196) is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy with the BAROSTIM NEO System in subjects with heart failure, defined as New York Heart Association (NYHA) functional Class III, left ventricular ejection fraction (LVEF) ≤ 35% and NT-proBNP\<1600 pg/ml despite being treated with the appropriate heart failure guideline directed therapy, excluding subjects eligible for or actively receiving Cardiac Resynchronization Therapy (CRT). The total trial duration is anticipated to be approximately 5 years; however, the duration of an individual subject enrollment will depend on when he or she entered…
From ClinicalTrials.gov, last updated 2026-03-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Cvrx, Inc. reported $33,665 in research payments for this study in 2025 (17 payments).
Products named: Barostim Neo System
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- $32,990
- Sterling Irb $675
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.